Mealey's (February 16, 2021, 1:54 PM EST) -- WASHINGTON, D.C. — In a blow to Amgen Inc. and two subsidiaries, the Federal Circuit U.S. Court of Appeals on Feb. 11 upheld findings by a federal judge in Delaware that three claims of two patents that describe antibodies that purportedly lower low-density lipoprotein (LDL) cholesterol are invalid for their lack of enablement....